- Published at
- by manilatimes.net
mixed
mixed
News for Ligand Pharmaceuticals Incorporated (LGND)
- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveLigand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $- Published at
- by gurufocus.com
mixedmixedLigand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening o- Published at
- by seekingalpha.com
neutralneutralLooking Back On Ligand Pharmaceuticals (NASDAQ:LGND)
Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn more about LGND stock here.- Published at
- by seekingalpha.com
neutralneutralLigand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsMelanie Herman - Senior...- Published at
- by investing.com
mixedmixed- Published at
- by investing.com
positivepositive- Published at
- by insidermonkey.com
positivepositiveLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript August 6, 2024Ligand Pharmaceuticals Incorporated misses on earnings expectations.- Published at
- by seekingalpha.com
mixedmixedLigand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:NASDAQ:LGND) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ETCompany ParticipantsTodd Davis - CEOTavo...- Published at
- by seekingalpha.com
neutralneutralLigand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation (NASDAQ:LGND)
The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2024 Q2 earnings call.- Published at
- by investing.com
positivepositiveLigand Pharmaceuticals boosts credit facility to $125 million By Investing.com
Ligand Pharmaceuticals boosts credit facility to $125 million- Published at
- by investing.com
mixedmixedLifecore Biomedical Announces Cooperation Agreement with 22NW By Investing.com
Lifecore Biomedical Announces Cooperation Agreement with 22NW- Published at
- by insidermonkey.com
positivepositiveLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.- Published at
- by gurufocus.com
positivepositiveQ1 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 07, 2024 / 08:30PM GMTOperator Thank you for standing by. Our name is Benjamin, and I will be your conference operator today. At this time, I would like to- Published at
- by benzinga.com
mixedmixedWhy Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session - Helix Energy Solns Gr (NYSE:HLX)
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.- Published at
- by benzinga.com
positivepositiveNorwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday - Norwegian Cruise Line (NYSE:NCLH)
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.- Published at
- by globenewswire.com
neutralneutralIn-Silico Drug Discovery Market in North America Holds A Significant Revenue Share - Explained In Detailed
Companies covered in this study are Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC.,...- Published at
- by marketscreener.com
mixedmixed- Published at
- by marketscreener.com
positivepositiveLigand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
TZIELD is the first and only FDA approved treatment to delay the onset of Stage 3 type 1 diabetes ...